Giving vaccines in a scenario where you do not have the production, logistical, or delivery capacity is just tempting mutation for immune escape.  Israel just posted an abject data point in that regard: a drop from 94% to 64% in terms of infection prevention from vaccination in 1 month, due largely to Delta.  The selective pressures will continue to be towards more immune escape and more severe disease in vaccinees(and likely others as collateral damage) to transmit the virus better.

Vaccines applied with poor coverage to a capably mutating virus are like indiscriminately using antibiotics against a bacteria and having half the patients not finish the full prescribed dose.  It's a set-up for immune escape in either case, and we have seen it happen in each case.

Vaccination can't really determine which precise antibodies the body generates, but these mAbs could be infused into people, and I'm very pleased to see Dr. Dutta and the authors highlight the importance of selectively using multiple mAbs to avoid applying selective pressure for escape.